Drugs for Myelofibrosis/Polycythemia Vera
Here are the drugs and financial support services available to patients receiving treatment for Myelofibrosis/Polycythemia Vera.
Inrebic (fedratinib) Capsules
Drug company: Celgene
Inrebic is a kinase inhibitor oral medication used for the
treatment of adult patients with intermediate-2 or high-risk
primary or secondary (post-polycythemia vera or post-essential
thrombocythemia) myelofibrosis, a type of chronic
Celgene Patient Support offers 3 financial assistance programs
for patients who have been prescribed Inrebic:
Celgene Commercial Co-pay Program
This program reduces the cost of Inrebic to $25 for eligible
patients who have commercial (private) insurance, with a
maximum benefit of $10,000 per year.
Celgene Patient Assistance Program
Patients with no insurance or with not enough insurance to
cover their medication, who meet certain financial criteria,
may be able to receive Inrebic for free.
Celgene Patient Support
This program connects patients who have public insurance
to outside resources that may help with the cost of copays,
deductibles, and insurance premiums.
Drug company: Incyte
Jakafi is a kinase inhibitor used for the treatment of patients
with intermediate- or high-risk myelofibrosis, including primary
myelofibrosis, post-polycythemia vera myelofibrosis,
and post-essential thrombocythemia
myelofibrosis, as well
as for patients with polycythemia vera who cannot use
or cannot benefit from treatment with hydroxyurea.
Myelofibrosis, polycythemia vera, and essential thrombocythemia
are 3 types of myeloproliferative neoplasms (or
MPNs), which are rare and chronic blood cancers and have
only a few approved treatments.
Incyte offers 3 financial assistance programs for patients
who are using Jakafi:
IncyteCARES Copay/Coinsurance Assistance Program
Patients with commercial or private insurance who are
eligible to receive Jakafi pay as little as $0 monthly. The
amount of savings will not exceed $11,977 monthly and
To enroll in this program, patients must call IncyteCARES
(855-452-5234) to determine eligibility; a membership
number is provided immediately and a copay/co-insurance
card is activated for eligible patients. To receive copay
assistance, patients must contact the specialty pharmacy
and provide copay information. Eligible patients experiencing
an insurance coverage delay can receive a free supply
IncyteCARES Patient Assistance Program
Patients without prescription drug coverage for Jakafi, or
those whose insurance has denied claims, may be eligible
to receive the drug free of charge through this program. To
enroll in this program, patients must reside in the United
States or Puerto Rico, have an annual household income of
less than $125,000 or 600% of the federal poverty level,
whichever is greater, and have a valid prescription for an
Patients and their providers must complete the enrollment
form and fax it to 855-525-7207 or mail it directly to the
address listed on the form.
IncyteCARES Temporary Access Program
Eligible patients who experience a delay in insurance coverage
may be able to receive a free 30-day supply of Jakafi.
Patients must have private or commercial coverage to
qualify for this program.
Table. Drugs Prescribed for Myelofibrosis or Polycythemia Vera
- Drug name (generic name)
- Drug company
- Patient support services
Last modified: April 7, 2021